CD79a antibody (PE)

Catalog No. ABIN2663582

The PE-conjugated Mouse Monoclonal anti-CD79a antibody (Clone HM47) (ABIN2663582) specifically detects CD79a in FACS. The antibody is reactive with Human samples.

Quick Overview for CD79a antibody (PE) (ABIN2663582)

Target: CD79a (CD79A) (B-cell antigen receptor complex-associated protein alpha chain (CD79A))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD79a antibody is conjugated to PE

Application: Flow Cytometry (FACS)

Clone: HM47

Product Details anti-CD79a Antibody (PE)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for CD79a

Target: CD79a (CD79A) (B-cell antigen receptor complex-associated protein alpha chain (CD79A))

Alternative Name: CD79a

Background: CD79a is a 47 kD type I integral membrane protein, also known as mb-1 or Iga. It is a member of the Ig superfamily and disulphide-associated with CD79b (B29). The interaction of CD79a/CD79b heterodimer with B cell suface Ig forms B cell antigen complex. CD79a is expressed in B cells from early pre-B to plasma cell stage. It has been shown that CD79a is also weakly expressed in some precursors of T- and myeloid cells.CD79 mediates the transport of IgM to B cell surface and transduces signals initiated by BCR aggregation

Pathways: BCR Signaling